VERA Vera Therapeutics
Vera Therapeutics earnings company data as of 7:50 PM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 5 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by VERA's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $250K bought by 1 insider
- $436K sold by 1 insider outside a trading plan
- $7M sold by 2 insiders under 10b5-1 plans
-
Marshall Fordyce CEOPlanned sale$685K 18,500 shares at $37.00 7.3% of stakeTraded Sep 15 Filed Sep 17
-
Marshall Fordyce CEOPlanned sale$650K 18,500 shares at $35.12 7.3% of stakeTraded Sep 2 Filed Sep 4
-
Marshall Fordyce CEOPlanned sale$2M 46,250 shares at $42.30 16% of stakeTraded Jul 7 Filed Aug 12
-
Marshall Fordyce CEOPlanned sale$702K 18,500 shares at $37.93 7.3% of stakeTraded Jun 23 Filed Aug 12
-
Marshall Fordyce CEOPlanned sale$680K 18,500 shares at $36.74 7.3% of stakeTraded May 12 Filed Aug 12
-
Marshall Fordyce CEOPlanned sale$1M 22,951 shares at $44.05 8.9% of stakeTraded Apr 14 Filed Apr 15
-
William D. Turner Chief Regulatory OfficerPlanned sale$501K 10,000 shares at $50.08 31% of stakeTraded Dec 15, 2025 Filed Dec 17, 2025
-
Patrick G Enright DirectorBuy$250K 5,882 shares at $42.50 New stakeTraded Dec 11, 2025 Filed Dec 15, 2025
-
William D. Turner Chief Regulatory OfficerPlanned sale$453K 10,000 shares at $45.31 31% of stakeTraded Dec 8, 2025 Filed Dec 10, 2025
-
William D. Turner Chief Regulatory OfficerPlanned sale$400K 10,000 shares at $40.00 31% of stakeTraded Dec 3, 2025 Filed Dec 4, 2025
-
Joseph R Young SVP, Finance, Chief Acct OffcrSale$436K 15,000 shares at $29.06 24% of stakeTraded Nov 11, 2025 Filed Nov 13, 2025
Also filed in the last 12 months, not counted as buying or selling: 11 option exercises, 9 stock grants, and 8 sales to cover taxes.
SEC filings
Recent issuer filings from EDGAR, 19 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 7.01,8.01,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 8.01 | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.02 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.